Back to Treatments

Treatment

Crizanlizumab

1
Conditions
15
Trials
750
Participants
65%
Average Safety

Condition Evidence

Sickle cell disorders

15 trials · 750 participants

65% effectiveness · 65% safety
Crizanlizumab | DFDA